| Name | Title | Contact Details |
|---|
MedAmerica is one of the leading healthcare practice management organizations in the United States. Since 1975, we have successfully managed hospital-based physician group practices across the Acute Care Continuum, with expertise in emergency medicine, hospital medicine, ambulatory & urgent care, and other acute care specialties. We provide the strategy, solutions, and systems to help our clients successfully navigate today’s complex healthcare landscape. MedAmerica offers a full range of cost-effective practice management solutions. We’re in the business of enabling physician groups, hospitals, and other healthcare organizations to be more efficient, productive, and profitable – all while providing higher quality care and improved outcomes.
Piatt County Mental Health Center is a Monticello, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Besafemeds takes today`s technology and applies it to healthcare to deliver a discreet treatment option for STDs. We store no identifiable data on our users. Once a determination is made that a prescription is needed and subsequently transmitted to the pharmacy of your choice, all identifiable data is purged from the system. Besafemeds is staffed by physicians and nurse practitioners following standard treatment guidelines for the two most common STDs (gonorrhea and chlamydia). In an ideal world, testing should occur before treatment. However, besafemeds is here for those who need or want a discreet and quick STD treatment option.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
Cook Pharmica is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Bloomington, IN. To find more information about Cook Pharmica, please visit www.cookpharmica.com